Saint Louis, MO (PRWEB) March 22, 2006
Nutra Pharma Corp. (OTC BB:NPHC.OB - News), a biotechnology company that is developing drugs for HIV and Several Sclerosis, has announced that Designer Diagnostics will be participating in a medical workshop organized to educate physicians in India about their Test Kits. Designer Diagnostics is a wholly owned subsidiary of Nutra Pharma.
The workshop will take location on March 24, 2006, at the Mahatma Gandhi Institute. Physicians will obtain CME credits for attending. The workshop will incorporate guest lecturers from the World Wellness Organization (WHO), JALMA Institute for Leprosy and other Mycobacterial Diseases, Grant Medical College, JJ Hospital Mumbai, the Mahatma Gandhi Institute, and Designer Diagnostics Inc. Invited to the CME are forty top Indian Microbiologists as properly as leading diagnostic test distributors.
"Included in the agenda will be an afternoon of demonstrations of Designer Diagnostics' paraffin slide culture to the participants," said Dr. Rahul Narang, Director of The Mahatma Gandhi Institute of Medicine's Department of Microbiology. "We shall demonstrate growth of non-tuberculous mycobacteria, biochemical reactions and drug sensitivity testing employing paraffin slide culture."
"The Designer Diagnostics Test Kits will be a great asset in the efforts to control both Tuberculosis mycobacterium and non-tubercular mycobacteria such as M.avium, which are main causes of death in HIV/AIDS patients," said Neil Roth, President of Designer Diagnostics Inc. "The rapid methods of determining the existence and sort of mycobacterium that the Test Kits bring to this important struggle can help dramatically decrease the suffering and deaths these diseases are causing right now. This conference will be crucial in sharing this information inside the active Tuberculosis and microbiology communities."
Attending the convention will be Neil Roth and Dr. Robert Ollar, representing Designer Diagnostics Inc., and Steven Wilson, representing HealthForce LLC, the consulting firm hired to sell and marketplace the Test Kits.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical organization specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. via its subsidiaries carries out basic drug discovery study and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc, is developing technologies for the production of drugs for HIV and Several Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics is engaged in the investigation and development of diagnostic test kits developed to be utilised for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and firms in the biotechnology arena.
http://www.NutraPharma.com
http://www.DesignerDiagnostics.com
This press release contains forward-searching statements. The words or phrases "would be," "will enable," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-searching statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") company plan. The Company's organization is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The participation in the Gandhi Institute workshop ought to not be construed as an indication in any way whatsoever of the value of the Business or its typical stock. The Company's filings may be accessed at the SEC's Edgar system at http://www.sec.gov. Statements produced herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Firm cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we particularly disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances following the date of such statement.
###
, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.
Uncover A lot more Mycobacterium Tuberculosis Test Press Releases
0 comments:
Post a Comment